AFP and viral hepatitis: Figure 2B, based on the numerical level, showed the clinico-pathological characteristics of patients which were significantly associated with preferable effectiveness on PFS after immunotherapy were patients in BCLC B, with viral hepatitis positivity, AFP less than 400 ng/ml, with EHS, with MVI and/or EHS, and received prior local therapy.